Skip to content

Physical Activity During Radiation Therapy for Lung Cancer

Assessment of Physical Activity During Radiation Therapy for LUNG Cancer

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07380815
Acronym
APART-LUNG
Enrollment
20
Registered
2026-02-02
Start date
2026-02-01
Completion date
2026-05-21
Last updated
2026-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prospective Study

Keywords

lung cancer, radiation therapy, physical activity

Brief summary

The primary objective of this trial is to evaluate patterns of physical activity during radiation therapy for lung cancer and to estimate the within-patient change in physical activity between Week 1 and Week 5 of radiation therapy, measured by smart phone-recorded step counts normalized for device carrying time. The trial is exploratory in nature with the aim to generate scientific hypotheses to be investigated in future clinical trials.

Detailed description

Lung cancer belongs to the most common types of solid cancer in Europe and Northern America. A considerable number of patients with lung cancer receive conventionally fractionated radiation therapy with or without systemic treatment. Radiation therapy may be associated with adverse events affecting healthy tissues within the radiation field but also with fatigue and a decreased level of physical activity or function. Patients who experience significant treatment-related toxicity may not be able to receive the complete radiation therapy as planned. Maintaining or even improving the level of activity by physical exercise or walking a certain number of steps per day may be helpful in this context. A benefit of exercise has been suggested in a retrospective study of 184 cancer patients receiving neoadjuvant chemotherapy, including 31 patients with lung cancer. Adherence to an exercise program was associated with fewer dose reductions and delays of chemotherapy. Moreover, several studies performed in patients with lung cancer suggested that physical activity had a positive effect on the patient's quality of live. Thus, physical activity prior to and during chemo- and/or immunotherapy for lung cancer appears important. This may also be true for patients with lung cancer treated with radiation therapy. However, adherence to an exercise program sometimes may be challenging for the patients, particularly if they experience treatment-related fatigue or other adverse events. The question arose whether an easy-to-use mobile app installed on the patient's smart phone reminding patients several times daily to perform a certain number of steps will have a positive effect on their physical activity during a course of radiation therapy. Such an app is planned to be tested in a prospective trial. However, step counts derived from smart phones are influenced by variability in device carrying time, as patients may not carry their phones consistently throughout the day. This variability introduces measurement heterogeneity that must be explicitly addressed in the statistical design and analysis. The present study is designed as a pilot investigation for this prospective trial to evaluate changes in physical activity during radiation therapy while establishing a robust and Good Clinical Practice (GCP)-compliant analytical framework for smart phone-derived step data. Physical activity is assessed during Week 1 and Week 5 of radiation therapy using a smart phone application. A total of approximately 20 patients qualifying for the Full Analysis Set are planned to be enrolled and documented. Recruitment of all patients should be completed within 3 months. This period also represents the total running time for this study. The study is designed as a pilot and feasibility investigation and is not intended to provide confirmatory evidence.

Interventions

None listed

Sponsors

University Hospital Schleswig-Holstein
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Histologically proven lung cancer 2. Treatment with ≥50 Gy of conventionally fractionated radiation therapy 3. Possession of and ability to use a smart phone plus a step counter 4. Age ≥18 years 5. Written informed consent 6. Capacity of the patient to consent

Exclusion criteria

1\. Expected Non-Compliance

Design outcomes

Primary

MeasureTime frameDescription
Mean number of steps per week during week 1 and week 5 of radiation therapy for lung cancerthrough study completion, 5 weeksThe primary endpoint is to assess the within-patient difference in weekly average steps per wear-hour of the smart phone (Week 5 minus Week 1 of radiation therapy). Any type of smart phone is allowed, as long as it has a step counter.

Secondary

MeasureTime frameDescription
Wear-time of the smart phonethrough study completion, 5 weeksThe mean wear-time of the smart phone per day (given in hours) during week 1 and week 5 of the radiation therapy course is assessed.

Countries

Denmark, Georgia, Germany, Slovenia

Contacts

PRINCIPAL_INVESTIGATORDirk Rades

University of Luebeck

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 3, 2026